Öz
Amaç
Bu çalışma anti-nötrofil sitoplazmik antikor ile ilişkili vaskülit (AAV) hastaları ile sağlıklı kontroller arasında tiyol/disülfit dengesinin ve iskemi modifiye albümin (IMA) düzeylerinin karşılaştırılması amacıyla hazırlanmıştır. Ayrıca bu çalışmada AVV’nin hastalık aktivite skoru ve organ tutulumları ile IMA ve tiyol/disülfit molekülleri arasındaki ilişkiler de araştırılmıştır.
Yöntem
Çalışmaya 46 AVV hastası ile 45 sağlıklı gönüllü dahil edildi. AVV hastalık aktivitesi için Birmingham vasculitis aktivite skoru (BVAS) version-3 kullanıldı. Disülfit (-SS), doğal tiyol (-SH) ve total tiyol (-SH+-SS) moleküllerine ait analizler otomatik spektrofotometrik metod ile, IMA’ya ait hesaplamalar ise albümin-kobalt bağlanma testi ile gerçekleştirildi. -SS/(-SH+-SS) oranında artış oksidasyon lehinde kayma, -SH/(-SH+-SS) oranında artış ise antioksidasyon lehinde kayma kabul edildi.
Bulgular
AVV grubunda kontrol grubuna göre -SS/(-SH+-SS) oranı anlamlı olarak daha yüksek [β: -0,482, risk oranı (OR) güven aralığı (GA) %95: 0,618 (0,432-0,882), p=0,008], -SH/(-SH+-SS) oranı ise daha düşük [β: 0,242, OR (GA %95): 1,273 (1,065-1,522), p=0,008] saptandı. -SH ile BVAS-3 arasında anlamlı bir korelasyon ilişkisi tespit edildi [β: -8,202, GA %95: -16,108- (-0,267), p=0,043].
Sonuç
AVV hastalarında sağlık kontrollere göre tiyol/disülfit molekülleri oksidasyon yönünde kaymıştır ve yüksek BVAS-3 hastalıkları skorları olan hastalar daha düşük serum tiyol düzeylerine sahiptir.
Anahtar Kelimeler: ANCA ilişkili vaskülit, tiyol, IMA, BVAS-3
Kaynakça
Yates M, Watts RA, Bajema I, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016;75:1583-94.
Koening CL, von Hennigs I. Antineutrophil cytoplasmic antibody (ANCA) vasculitis: pathophysiology, diagnosis, and the evolving treatment landscape. Am J Manag Care. 2021;27(15 Suppl):S267-76.
Hellmich B, Flossmann O, Gross WL, et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis. 2007;66:605-17.
Yates M, Watts R. ANCA-associated vasculitis. Clin Med (Lond). 2017;17:60-4.
Borderie D, Allanore Y, Meune C, Devaux JY, Ekindjian OG, Kahan A. High ischemia-modified albumin concentration reflects oxidative stress but not myocardial involvement in systemic sclerosis. Clin Chem. 2004;50:2190-3.
Apple FS, Quist HE, Otto AP, Mathews WE, Murakami MM. Release characteristics of cardiac biomarkers and ischemia-modified albumin as measured by the albumin cobalt-binding test after a marathon race. Clin Chem. 2002;48:1097-100.
Bhagavan NV, Lai EM, Rios PA, et al. Evaluation of human serum albumin cobalt binding assay for the assessment of myocardial ischemia and myocardial infarction. Clin Chem. 2003;49:581-5.
Piva SJ, Duarte MM, Da Cruz IB, et al. Ischemia-modified albumin as an oxidative stress biomarker in obesity. Clinical Biochem. 2011;44:345-7.
Caglar GS, Oztas E, Karadag D, Pabuccu R, Demirtas S. Ischemia-modified albumin and cardiovascular risk markers in polycystic ovary syndrome with or without insulin resistance. Fertil Steril. 2011;95:310-3.
Duarte MM, Rocha JB, Moresco RN, et al. Association between ischemia-modified albumin, lipids and inflammation biomarkers in patients with hypercholesterolemia. Clin Biochem. 2009;42:666-71.
Bonorino NF, Lunardelli A, Oliveira JR. Use of ischemia modified albumin for the diagnosis of myocardial infarction. J Bras Patol Med Lab. 2015;51:383-8.
Leitemperguer MR, Tatsch E, Kober H, De Carvalho J, Moresco RN, Da Silva J. Assessment of ischemia-modified albumin levels in patients with rheumatoid arthritis. Clin Lab. 2014;60:1065-70.
Özdemir M, Kiyici A, Balevi A, Mevlitoğlu I, Peru C. Assessment of ischaemia-modified albumin level in patients with psoriasis. Clin Exp Dermatol. 2012;37:610-4.
Türkön H, Gökmen F, Çakir DÜ, Sehitoğlu MH, Reşorlu H, Döner D, et al. Increased levels of serum ischemia modified albumin in patients with ankylosing spondylitis. Clin Lab. 2016;62:645-9.
Kor A, Maraş Y, Atalar E, Oğuz EF, Gök K, Erel Ö. Ischemia-modified albumin levels are elevated, and thiol/disulfite homeostasis is impaired in Behçet’s disease. J Turk Soc Rheumatol. 2022;14:15-22.
Kucuk A, Uslu AU, Arslan S, et al. Ischemia-modified albumin and atherosclerosis in patients with familial Mediterranean fever. Angiology. 2016;67:456-60.
Balik AR, Omma A, Sandikci SC, et al. Evaluation of oxidative stress in gout disease; thiol-disulfide homeostasis and ischemia-modified albumin levels. Int J Med Biochem. 2022;5:109-15.
Montagnana M, Lippi G, Volpe A, et al. Evaluation of cardiac laboratory markers in patients with systemic sclerosis. Clin Biochem. 2006;39:913-7.
Omma A, Colak S, Can Sandikci S, et al. Serum neopterin and ischemia modified albumin levels are associated with the disease activity of adult immunoglobulin A vasculitis (Henoch-Schönlein purpura). Int J Rheum Dis. 2019;22:1920-5.
Dickinson DA, Forman HJ. Cellular glutathione and thiols metabolism. Biochem Pharmacol. 2002;64:1019-26.
Cuozzo JW, Kaiser CA. Competition between glutathione and protein thiols for disulphide-bond formation. Nat Cell Biol. 1999;1:130-5.
Deneke SM. Thiol-based antioxidants. Curr Top Cell Regul. 2001;36:151-80.
Lushchak VI. Glutathione homeostasis and functions: potential targets for medical interventions. J Amino Acids. 2012;2012:736837.
Rossi R, Giustarini D, Milzani A, Dalle-Donne I. Cysteinylation and homocysteinylation of plasma protein thiols during ageing of healthy human beings. J Cell Mol Med. 2009;13:3131-40.
Kor A, Akan S, Oğuz EF, Maraş Y, Neşelioğlu S, Erten Ş. The thiol/disulfide balance is shifted towards oxidation in psoriatic arthritis compared to controls and is associated with higher disease activity. Lab Med. 2024:lmae014.
Polat YH, Erten Ş, Kor A, et al. Evaluation of thiol/disulfide homeostasis in rheumatoid arthritis and disease activity. Clin Biochem. 2023;111:81-6.
Baykara RA, Tuzcu A, Omma A, et al. Evaluation of serum thiol/disulfide homeostasis in patients with ankylosing spondylitis by a novel method. North Clin Istanb. 2019;6.
Omma A, Sandikci SC, Kücüksahin O, Alisik M, Erel O. Can the thiol/disulfide imbalance be a predictor of colchicine resistance in familial Mediterranean fever? J Korean Med Sci. 2017;32:1588-94.
Kaman A, Aydın Teke T, Gayretli Aydın ZG, et al. Dynamic thiol/disulphide homeostasis and pathogenesis of Kawasaki disease. Pediatr Int. 2019;61:913-8.
Yilmaz CN, Gemcioglu E, Baser S, Erten S, Erel O. Thiol/disulfide homeostasis impaired in patients with primary Sjögren’s syndrome. J Med Biochem. 2021;40:270.
Lalwani P, de Souza GKBB, de Lima DSN, Passos LFS, Boechat AL, Lima ES. Serum thiols as a biomarker of disease activity in lupus nephritis. PLoS One. 2015;10:e0119947.
Jennette JC. Overview of the 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Clin Exp Nephrol. 2013;17:603-6.
Mukhtyar C, Lee R, Brown D, et al. Modification and validation of the Birmingham vasculitis activity score (version 3). Ann Rheum Dis. 2009;68:1827-32.
Erel O, Neselioglu S. A novel and automated assay for thiol/disulphide homeostasis. Clin Biochem. 2014;47:326-32.
Bar–Or D, Lau E, Winkler JV. A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia—a preliminary report. J Emerg Med. 2000;19:311-5.
Bossuyt X, Cohen Tervaert J-W, Arimura Y, et al. Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis. Nat Rev Rheumatol. 2017;13:683-92.
Ece A, Kelekçi S, Kocamaz H, et al. Antioxidant enzyme activities, lipid peroxidation, and total antioxidant status in children with Henoch–Schönlein purpura. Clin Rheumatol. 2008;27:163-9.
Demircin G, öuner A, Ünver Y, Bülbül M, Erdoĝan Ö. Erythrocyte superoxide dismutase activity and plasma malondialdehyde levels in children with Henoch Schönlein purpura. Acta Pædiatr. 1998;87:848-52.
Buyan N, Erbaş D, Akkök N, Öz E, Biberoğlu G, Hasanoğlu E. Role of free oxygen radicals and prostanoids in the pathogenesis of Henoch-Schönlein purpura. Prostaglandins Leukot Essent Fatty Acids. 1998;59:181-4.
Keskin N, Civilibal M, Elevli M, Koldas M, Duru NS, Ozturk H. Elevated plasma advanced oxidation protein products in children with Henoch–Schonlein purpura. Pediatr Nephrol. 2011;26:1989-93.
Guilpain P, Servettaz A, Goulvestre C, et al. Pathogenic effects of antimyeloperoxidase antibodies in patients with microscopic polyangiitis. Arthritis Rheum. 2007;56:2455-63.
Witko-Sarsat V, Friedlander M, Capeillère-Blandin C, et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int. 1996;49:1304-13.
Okamura DM, Himmelfarb J. Tipping the redox balance of oxidative stress in fibrogenic pathways in chronic kidney disease. Pediatr Nephrol. 2009;24:2309-19.
Laurent A, Nicco C, Chéreau C, et al. Controlling tumor growth by modulating endogenous production of reactive oxygen species. Cancer Res. 2005;65:948-56.
Maria AT, Toupet K, Bony C, et al. Antifibrotic, antioxidant, and immunomodulatory effects of mesenchymal stem cells in HOCl‐induced systemic sclerosis. Arthritis Rheumatol. 2016;68:1013-25.
Poli G, Parola M. Oxidative damage and fibrogenesis. Free Radic Biol Med. 1997;22:287-305.
Servettaz A, Guilpain P, Goulvestre C, et al. Radical oxygen species production induced by advanced oxidation protein products predicts clinical evolution and response to treatment in systemic sclerosis. Ann Rheum Dis. 2007;66:1202-9.
Guilpain P, Chéreau C, Goulvestre C, et al. The oxidation induced by anti-MPO antibodies triggers fibrosis in microscopic polyangiitis. Eur Respir J. 2010;37:1503-13.
Atalay M, Marnila P, Lilius E-M, Hänninen O, Sen CK. Glutathione-dependent modulation of exhausting exercise-induced changes in neutrophil function of rats. Eur J Appl Physiol Occup Physiol. 1996;74:342-7.
Sen CK, Packer L. Thiol homeostasis and supplements in physical exercise. Am J Clin Nutr. 2000;72:653S-69S.
Van Antwerpen P, Boudjeltia KZ, Babar S, et al. Thiol-containing molecules interact with the myeloperoxidase/H2O2/chloride system to inhibit LDL oxidation. Biochem Biophys Res Commun. 2005;337:82-8.
Vasu VT, De Cruz SJ, Houghton JS, Hayakawa KA, Morrissey BM, Cross CE, et al. Evaluation of thiol-based antioxidant therapeutics in cystic fibrosis sputum: focus on myeloperoxidase. Free Radic Res. 2011;45:165-76.
Kadioğlu H, Ömür D, Bozkurt S, et al. Ischemia modified albumin can predict necrosis at incarcerated hernias. Dis Markers. 2013;35:807-10.
Valle Gottlieb MG, da Cruz IBMn, Duarte MM, et al. Associations among metabolic syndrome, ischemia, inflammatory, oxidatives, and lipids biomarkers. J Clin Endocrinol Metab. 2010;95:586-91.
Dominguez-Rodriguez A, Abreu-Gonzalez P. Current role of ischemia-modified albumin in routine clinical practice. Biomarkers. 2010;15:655-62.
Ahn SS, Yoon T, Song JJ, Park Y-B, Lee S-W. Serum albumin, prealbumin, and ischemia-modified albumin levels in patients with ANCA-associated vasculitis: a prospective cohort study. PloS One. 2022;17:e0271055.
Hilhorst M, Maria AT, Kavian N, Batteux F, et al. Impact of MPO-ANCA-mediated oxidative imbalance on renal vasculitis. Am J Physiol Renal Physiol. 2018;315:F1769-76.
